Last reviewed · How we verify

Colistin/Polymyxin B + Tigecycline/Eravacycline

National University of Singapore · FDA-approved active Small molecule

Colistin/Polymyxin B + Tigecycline/Eravacycline is a Polymyxin + tetracycline combination antibiotic Small molecule drug developed by National University of Singapore. It is currently FDA-approved for Multidrug-resistant gram-negative bacterial infections, Extensively drug-resistant Acinetobacter baumannii infections, Carbapenem-resistant Enterobacteriaceae infections.

This combination uses colistin/polymyxin B to disrupt bacterial cell membranes while tigecycline/eravacycline inhibits protein synthesis, providing synergistic activity against multidrug-resistant gram-negative bacteria.

This combination uses colistin/polymyxin B to disrupt bacterial cell membranes while tigecycline/eravacycline inhibits protein synthesis, providing synergistic activity against multidrug-resistant gram-negative bacteria. Used for Multidrug-resistant gram-negative bacterial infections, Extensively drug-resistant Acinetobacter baumannii infections, Carbapenem-resistant Enterobacteriaceae infections.

At a glance

Generic nameColistin/Polymyxin B + Tigecycline/Eravacycline
SponsorNational University of Singapore
Drug classPolymyxin + tetracycline combination antibiotic
TargetBacterial cell membrane (polymyxins) and 30S ribosome (tetracyclines)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Colistin and polymyxin B are polymyxin antibiotics that bind to and disrupt the outer membrane of gram-negative bacteria, causing cell lysis. Tigecycline and eravacycline are tetracycline-class antibiotics that inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit. The combination exploits different mechanisms to overcome resistance and achieve enhanced bactericidal activity against extensively drug-resistant pathogens.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Colistin/Polymyxin B + Tigecycline/Eravacycline

What is Colistin/Polymyxin B + Tigecycline/Eravacycline?

Colistin/Polymyxin B + Tigecycline/Eravacycline is a Polymyxin + tetracycline combination antibiotic drug developed by National University of Singapore, indicated for Multidrug-resistant gram-negative bacterial infections, Extensively drug-resistant Acinetobacter baumannii infections, Carbapenem-resistant Enterobacteriaceae infections.

How does Colistin/Polymyxin B + Tigecycline/Eravacycline work?

This combination uses colistin/polymyxin B to disrupt bacterial cell membranes while tigecycline/eravacycline inhibits protein synthesis, providing synergistic activity against multidrug-resistant gram-negative bacteria.

What is Colistin/Polymyxin B + Tigecycline/Eravacycline used for?

Colistin/Polymyxin B + Tigecycline/Eravacycline is indicated for Multidrug-resistant gram-negative bacterial infections, Extensively drug-resistant Acinetobacter baumannii infections, Carbapenem-resistant Enterobacteriaceae infections.

Who makes Colistin/Polymyxin B + Tigecycline/Eravacycline?

Colistin/Polymyxin B + Tigecycline/Eravacycline is developed and marketed by National University of Singapore (see full National University of Singapore pipeline at /company/national-university-of-singapore).

What drug class is Colistin/Polymyxin B + Tigecycline/Eravacycline in?

Colistin/Polymyxin B + Tigecycline/Eravacycline belongs to the Polymyxin + tetracycline combination antibiotic class. See all Polymyxin + tetracycline combination antibiotic drugs at /class/polymyxin-tetracycline-combination-antibiotic.

What development phase is Colistin/Polymyxin B + Tigecycline/Eravacycline in?

Colistin/Polymyxin B + Tigecycline/Eravacycline is FDA-approved (marketed).

What are the side effects of Colistin/Polymyxin B + Tigecycline/Eravacycline?

Common side effects of Colistin/Polymyxin B + Tigecycline/Eravacycline include Nephrotoxicity, Neurotoxicity, Gastrointestinal disturbances, Photosensitivity.

What does Colistin/Polymyxin B + Tigecycline/Eravacycline target?

Colistin/Polymyxin B + Tigecycline/Eravacycline targets Bacterial cell membrane (polymyxins) and 30S ribosome (tetracyclines) and is a Polymyxin + tetracycline combination antibiotic.

Related